Profund Advisors LLC Buys 7,227 Shares of Kymera Therapeutics, Inc. $KYMR

Profund Advisors LLC raised its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 48.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 22,240 shares of the company’s stock after purchasing an additional 7,227 shares during the period. Profund Advisors LLC’s holdings in Kymera Therapeutics were worth $1,730,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. US Bancorp DE boosted its holdings in Kymera Therapeutics by 9.8% in the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after purchasing an additional 166 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Kymera Therapeutics by 9.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock valued at $156,000 after purchasing an additional 248 shares during the period. Larson Financial Group LLC boosted its holdings in Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in Kymera Therapeutics by 2.2% in the 4th quarter. Harbor Capital Advisors Inc. now owns 30,573 shares of the company’s stock valued at $2,379,000 after purchasing an additional 645 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Kymera Therapeutics by 5.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,631 shares of the company’s stock valued at $1,216,000 after purchasing an additional 789 shares during the period.

Analyst Ratings Changes

KYMR has been the subject of a number of recent research reports. BTIG Research cut their price objective on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Piper Sandler boosted their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, February 26th. Barclays boosted their price objective on shares of Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a report on Tuesday, January 27th. Morgan Stanley reissued an “overweight” rating and issued a $119.00 price objective on shares of Kymera Therapeutics in a report on Thursday, April 30th. Finally, Citigroup boosted their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $118.10.

Insider Activity at Kymera Therapeutics

In other news, Director Bruce Booth sold 5,900 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $89.96, for a total transaction of $530,764.00. Following the completion of the sale, the director owned 5,641 shares of the company’s stock, valued at approximately $507,464.36. This represents a 51.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Elena Ridloff sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $87.00, for a total transaction of $261,000.00. Following the transaction, the director owned 3,000 shares of the company’s stock, valued at approximately $261,000. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 383,734 shares of company stock worth $32,454,902 in the last 90 days. Corporate insiders own 15.98% of the company’s stock.

Kymera Therapeutics Trading Up 3.2%

Shares of Kymera Therapeutics stock opened at $80.65 on Thursday. The company has a 50 day moving average of $83.31 and a 200-day moving average of $78.44. Kymera Therapeutics, Inc. has a 1-year low of $28.06 and a 1-year high of $103.00. The company has a market cap of $6.63 billion, a PE ratio of -22.59 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same quarter in the prior year, the firm posted ($0.82) EPS. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. Research analysts forecast that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.